as 05-30-2025 4:00pm EST
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
Founded: | 2011 | Country: | United States |
Employees: | N/A | City: | BERKELEY |
Market Cap: | 93.0M | IPO Year: | 2021 |
Target Price: | $8.50 | AVG Volume (30 days): | 943.1K |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.62 | EPS Growth: | N/A |
52 Week Low/High: | $0.66 - $3.00 | Next Earning Date: | 05-08-2025 |
Revenue: | $9,918,000 | Revenue Growth: | -70.31% |
Revenue Growth (this year): | -1.28% | Revenue Growth (next year): | 161.81% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Haurwitz Rachel E. | CRBU | President and CEO | Mar 14 '25 | Buy | $1.02 | 20,000 | $20,400.00 | 3,369,395 |
CRBU Breaking Stock News: Dive into CRBU Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Simply Wall St.
11 days ago
Zacks
18 days ago
MT Newswires
23 days ago
Zacks
23 days ago
GlobeNewswire
23 days ago
GlobeNewswire
25 days ago
Zacks
a month ago
The information presented on this page, "CRBU Caribou Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.